Thrombosis Associated with Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Venous thromboembolism (VTE), the most prevalent form of cancer-related thrombosis, is the main cause of death in cancer patients. Chemotherapy and immobilization are two risk factors for developing VTE that are linked to cancer patients. When compared to non-cancer patients, these risk factors raise the likelihood of cancer in VTE patients. According to estimates, there are 1-2 cases of VTE per 1,000 person-years in Europe and the US, but the incidence varies greatly by age, sex, ethnicity, and health status. In comparison to Europe and the US, Asia is thought to have lower rates of VTE. Patients with cancer still have very few options for venous thromboembolism (VTE) treatment. Although long-term treatment with initial parenteral anticoagulants followed by vitamin K antagonists has been compared to low-molecular-weight heparin monotherapy as a straightforward and effective treatment option, many clinical questions remain unanswered.

Description

The most frequent type of venous thromboembolism (VTE), which is caused by thrombosis associated with cancer, is the main cause of death in cancer patients. Chemotherapy and immobilization are two risk factors for developing VTE that are connected to cancer patients. When compared to non-cancer patients, these risk factors raise the likelihood of cancer in VTE patients. Many of the same anticancer treatments are being promoted as additional mechanisms for inducing VTE. Cancer cells can activate the coagulation cascade and other coagulation properties of host cells. Cancer frequently results in a number of side effects, such as neutropenia, metastases, and alopecia. Venous thromboembolism (VTE), also known as cancer-associated thrombosis (CAT), is a less common complication. Although VTE happens to one in five cancer patients, both patients and medical professionals tend to be unaware of the condition. Deep vein thrombosis, pulmonary embolism, and other types of thrombosis are collectively referred to as VTE. Approximately 1 in 1,000 people in the US experience it annually, according to a study. In addition, CAT causes 20-30% of all VTEs. With a 2.2-fold increase in mortality compared to cancer patients without CAT, CAT is a significant cause of morbidity and mortality in cancer patients. Studies contrasting cancer patients with non-cancer patients reveal that cancer patients have a 2-fold higher risk of bleeding and a 4-7-fold higher risk of venous thromboembolism. The leading cause of death during chemotherapy (i.e., CAT) is the second-leading cause of death in cancer patients after disease progression (i.e., compared to neutrophil sepsis). Patients with CAT do not always experience symptoms; up to half of cases are discovered by chance during testing. The risk of recurrence was highest in the months immediately following diagnosis in patients with CAT (9.6 per 100 patient-years). To put this figure in perspective, consider that one of the populations most at risk for VTE recurrence is men without cancer who have been diagnosed with unprovoked proximal DVT. This recurrence rate is comparable to that seen in this population. In comparison to non-cancer patients, cancer patients had a three times higher risk of recurrence and were more likely to experience another VTE within six months of diagnosis (22% in cancer patients vs. 6% of patients with diseases other than cancer.

Thrombosis Associated with Cancer (Epidemiology)

VTE is thought to occur in 1-2 cases per 1,000 person-years in Europe and the US, but this number varies greatly by age, sex, ethnicity, and state of health. As compared to Europe and the US, Asia is thought to have lower rates of VTE. According to estimates, there are 0 points 2 cases of VTE per 1000 person-years in Korea, for instance. South America and Oceania have less data available. Incidence of VTE was reported to be 0.7 per 1,000 person-years in Buenos Aires, Argentina, and 0.8 per 1,000 person-years in Perth, Australia. The incidence of VTE in Africa is not well understood. The United States and Europe provide the most precise information on the incidence of VTE. According to the American Heart Association's 2021 report, there are an estimated 1,220,000 VTE cases in the country each year. This estimate is based on previously unpublished national hospitalization data that indicates there were 857,000 cases of DVT and 370,000 cases of pulmonary embolism in 2016. It also assumes that 30% of DVT cases are ambulatory. In six European countries (with a combined population of 310.4 million), modeling studies estimated the annual incidence of VTE at 296,000 cases of PE and 466,000 cases of DVT. According to population studies, the incidence of VTE among cancer patients ranges from 1 to 9 per 1000 person-years. In Asia, the incidence of CAT is much higher than the incidence of non-cancerous VTE in the general population, and cancer may be the main cause of VTE. Studies conducted in hospitals using a heterogeneous study design revealed that the incidence of VTE varied greatly between cancer patients-from 0 to 44%-and VTE patients-ranging from 6 to 65%. Asian and Western studies found similar cancer sites and risk factors that were most associated with VTE. Although antithrombotic prophylaxis is not frequently used and there are no validated risk assessment tools, CAT has a significant impact on survival in Asian cancer patients.

Thrombosis Associated with Cancer -Current Market Size & Forecast Trends

The market for thrombosis associated with cancer is anticipated to grow significantly, driven by the increasing incidence of venous thromboembolism (VTE) among cancer patients. The venous thromboembolism market, which includes cancer-associated thrombosis, was valued at about USD 3.8 billion in 2023 and is expected to reach USD 7.0 billion by 2034, exhibiting a CAGR of 5.71%. The rising awareness of the risks associated with thrombosis in cancer patients, along with advancements in treatment options such as direct oral anticoagulants and novel therapies, are key factors contributing to this growth. North America is projected to hold a significant share of the market due to higher prevalence rates and advanced healthcare systems, while the Asia-Pacific region is expected to see rapid growth as healthcare access improves. Overall, the market for thrombosis associated with cancer is well-positioned for substantial expansion through 2035 as new treatments and strategies continue to emerge.

Patients with cancer still have very few options for venous thromboembolism (VTE) treatment. Although long-term treatment with initial parenteral anticoagulants followed by vitamin K antagonists has been described as a simple and effective treatment option, many clinical questions still need to be resolved. These include managing recurrent venous thromboembolism, managing patients with concurrent bleeding, and managing patients at high risk of bleeding. As randomized controlled trials of cancer-related thrombosis are largely unavailable, consensus clinical guidelines for treatment are based primarily on retrospective reports or extrapolated data from VTE populations without cancer. In addition, we must manage symptomatic VTE, which poses special challenges due to advances in imaging technology, increased cancer patient survival rates, and other factors. Therapeutic anticoagulants are the mainstay of treatment for these patients because they lower the risk of recurrence and prevent thrombosis. There is a higher risk of recurrent thromboembolism and tumor bleeding, despite the fact that therapeutic anticoagulants complicate the management of these patients. Due to its superior efficacy over vitamin K antagonists with comparable tolerance, low-molecular-weight heparin has recently become the preferred medication. The current standard of care for cancer-associated VTE (CA-VTE) is treatment with low molecular weight heparin (LMWH) for 3-6 months. New options for long-term anticoagulation in VTE include oral factor Xa inhibitors (FXaIs), including apixaban, edoxaban, and rivaroxaban. These medications have many benefits for cancer patients and can mitigate many of the drawbacks of LMWH therapy.

Report Highlights

Thrombosis Associated with Cancer - Current Market Trends

Thrombosis Associated with Cancer - Current & Forecasted Cases across the G8 Countries

Thrombosis Associated with Cancer - Market Opportunities and Sales Potential for Agents

Thrombosis Associated with Cancer - Patient-based Market Forecast to 2035

Thrombosis Associated with Cancer - Untapped Business Opportunities

Thrombosis Associated with Cancer - Product Positioning Vis-a-vis Competitors' Products

Thrombosis Associated with Cancer - KOLs Insight